Inhibrx Biosciences, Inc.
INBX
$111.34
-$1.53-1.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -138.18M | -130.19M | -140.06M | -155.09M | -163.69M |
| Total Depreciation and Amortization | 2.21M | 2.35M | 2.48M | 2.61M | 2.79M |
| Total Amortization of Deferred Charges | 3.30M | 2.64M | 2.44M | 1.80M | 1.16M |
| Total Other Non-Cash Items | 13.61M | 13.21M | 12.95M | 13.18M | 13.01M |
| Change in Net Operating Assets | -12.82M | -19.93M | -7.61M | -5.90M | 6.89M |
| Cash from Operations | -131.89M | -131.93M | -129.79M | -143.39M | -139.85M |
| Capital Expenditure | -10.00K | -10.00K | -31.00K | -47.00K | -284.00K |
| Sale of Property, Plant, and Equipment | 3.00K | 3.00K | 3.00K | 3.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7.00K | -7.00K | -28.00K | -44.00K | -284.00K |
| Total Debt Issued | 74.99M | 74.99M | 99.97M | 99.97M | 99.97M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.68M | 2.08M | 1.61M | 352.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -125.00K | -125.00K | -125.00K |
| Cash from Financing | 78.67M | 77.07M | 101.45M | 100.19M | 99.84M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.22M | -54.86M | -28.38M | -43.24M | -40.29M |